Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Research Physicians Network LLC

Neither a doctor nor a teaching hospital

Research payments

$5,299,314

555 payments

Through program year 2025, Research Physicians Network LLC is reported as receiving $5,299,314 in research payments, across 555 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,855,416 179
2024 Research $1,272,814 162
2023 Research $1,614,813 104
2022 Research $26,311 7
2021 Research $103,868 23
2020 Research $224,550 45
2019 Research $201,542 35

Breakdown

Who paid Research payments · program years 2019–2025
  1. Genentech, Inc. $3,420,443 336 payments
  2. AbbVie, Inc. $1,042,541 72 payments
  3. Allergan Inc. $326,565 71 payments
  4. Exact Sciences Corporation $117,412 16 payments
  5. Amgen Inc. $106,575 2 payments
  6. Verona Pharma, Inc. $68,181 16 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $48,508 12 payments
  8. Sanofi-Aventis U.S. LLC $42,883 4 payments
  9. Genzyme Corporation $37,459 9 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $31,070 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. Roche Cancer Screening Collection Study $3,061,376 273 payments
  2. A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants $719,275 20 payments
  3. PH III Study to Evaluate the Efficacy and Safety of Astegolimab in COPD $170,960 38 payments
  4. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $133,742 11 payments
  5. Transmission Study Household $121,241 11 payments
  6. Informed Choice Intervention for Colorectal Cancer Screening - COMPASS $107,332 8 payments
  7. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity $102,025 1 payment
  8. A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $75,956 18 payments
  9. A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD $68,181 16 payments
  10. M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants $67,229 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record